CN104644669A - Plasma substitute medicine composition used in first aid and preparation method thereof - Google Patents
Plasma substitute medicine composition used in first aid and preparation method thereof Download PDFInfo
- Publication number
- CN104644669A CN104644669A CN201310585559.0A CN201310585559A CN104644669A CN 104644669 A CN104644669 A CN 104644669A CN 201310585559 A CN201310585559 A CN 201310585559A CN 104644669 A CN104644669 A CN 104644669A
- Authority
- CN
- China
- Prior art keywords
- medicine composition
- hetastarch
- pharmaceutical composition
- sodium chloride
- plasma substitute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a plasma substitute medicine composition used in first aid and a preparation method thereof. The plasma substitutes medicine composition includes 2-4.5% (w/v) of sodium chloride and 3-7% (w/v) of hydroxyethyl starch, wherein the average molecular weight of the hydroxyethyl starch is 130000 +/- 20000 Dolton. The plasma substitute medicine composition is strong in plasma volume expansion, is durable in effects, is low in tendency of medicine accumulation, is high in safety and is more less in influence on blood coagulation in human body. The plasma substitute medicine composition can be used for treating hemorrhagic shock due to various reasons and can be used for rescue of injury and burn patients. The plasma substitute medicine composition can be used in various operations.
Description
Technical field
Plasma substitute pharmaceutical composition that the present invention relates to first aid and preparation method thereof, belongs to pharmaceutical composition technical field.
Background technology
The tradition recovery of hemorrhagic shock is with isotonic crystalloid fluid and/or early stage, quick, the enough input of colloidal solution, to recover hemodynamics as early as possible for target, after often there is recovery, Splanchnic oxygenation is not enough, systemic inflammatory response syndrome (SIRS), even develops into Multiple Organ Dysfunction Syndrome (MODS).Current adult respiratory distress syndrome (ARDS) and MODS postpone main causes of death after patients with traumatic-hemorrhagic shock recovery.Can alleviate the method for resuscitation of the rear inflammatory reaction of recovery and organ injury, be the focus for the treatment of hemorrhagic shock at present.
Compared with isosmotic solution, hyperosmotic solution has the advantage suppressing neutrophilic granulocyte activation and reduce inflammation damage, and Small volume resuscitation can obtain satisfied hemodynamic effect, and the first aid be applied to before battlefield and hospital has is convenient to transport, advantage easy to implement.
In order to solve the problem causing various Hematogenic infectious disease existing for blood transfusion, technical staff once research Hypertonic NaCl solution treats hemorrhagic shock.Hyperosmotic solution is 7.5%(w/v such as) sodium chloride, 7.2% sodium chloride, but the sodium chloride that this height oozes concentration has certain toxicity to body, often cause complication, such as hypotension, too highly ooze blood cell breakage, cardiac insufficiency, renal hypofunction and the nervous system disorders etc. that cause.
Current existing blood plasma substitute well can't meet the needs of clinical practice, also needs better plasma substitute pharmaceutical composition to be applied to the first aid field of the sick and wounded, is particularly applied to the rescue of the hemorrhagic shock that acute injury causes.
Summary of the invention
Plasma substitute pharmaceutical composition that the invention provides a kind of first aid and preparation method thereof.
Technical scheme of the present invention is as follows:
A kind of plasma substitute pharmaceutical composition, comprise 2-4.5%(w/v, namely in 100mL compositions containing 2-4.5g) sodium chloride and 3-7%(w/v, namely in 100mL compositions containing 3-7g) hetastarch, and the water for injection of surplus, wherein, the mean molecule quantity of described hetastarch is 130000 ± 20000 dalton.
Preferably, described plasma substitute pharmaceutical composition comprises 4.2%(w/v) sodium chloride and 6%(w/v) hetastarch.
Preferably, described hetastarch mean molecule quantity is 130000 ± 20000 dalton, and degree of exchange is 0.4 ± 0.1.
Preferably, described hetastarch mean molecule quantity is 130000 ± 20000 dalton, and degree of exchange is 0.4 ± 0.1, C2: C6 be greater than 8.
Alleged by the present invention, degree of exchange is also called substitution value.
The preparation method of pharmaceutical composition of the present invention is as follows:
Hetastarch is dissolved in water for injection, and 80-95 DEG C of agitating heating 10-20 minute, adds sodium chloride stirring and dissolving, 80-95 DEG C of agitating heating 5-20 minute, and filter, fill, sterilizing, to obtain final product.
The present invention adopts certain density hetastarch and sodium chloride solution as plasma substitute pharmaceutical composition, has the following advantages:
When 1, avoiding using blood transfusion mode to treat hemorrhagic shock, the Hematogenic infectious disease brought, such as HIV virus, hepatitis C virus etc.Compared with blood, pharmaceutical composition room temperature of the present invention is preserved.
2, use the sodium chloride of 4.2% concentration to form hyperosmotic solution, compared with isosmotic solution, the consumption of plasma substitute solution can be reduced, reduce the edema because isosmotic solution causes, heart, kidney overload; And compared with isosmotic solution, can onset in short-term, obviously can improve symptom of losing blood in 5-10 minute; It also avoid the various complication caused by sodium chloride hyperosmotic solution of 7.5% or 7.2% concentration simultaneously, such as hypotension, too highly ooze blood cell breakage, cardiac insufficiency, renal hypofunction and the nervous system disorders etc. that cause.
3, mean molecule quantity 130 is used, 000 daltonian hetastarch is as colloid, form colloid solution, with molecular weight 25,000-45, the hydroxyethyl starch solution of 000 is compared, and blood plasma dilatation is strong, effect lasting, drug accumulation tendency is low, safety is high, less on the impact of human body blood coagulation effect.
The purposes of pharmaceutical composition of the present invention is be used for the treatment of the hemorrhagic shock that a variety of causes causes, and is used for the rescue of wound, burn patient, uses in various operation as blood plasma substitute as blood plasma substitute.
Detailed description of the invention
The invention will be further described by the following examples, but this is not limitation of the present invention, those skilled in the art, according to basic thought of the present invention, can make various amendment or improvement, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
Embodiment 1:
Prepared by hetastarch 130/0.4 crude drug: with side chain corn starch for initiation material, through hydrolysis, hydroxyethylation, refining to obtain.
Embodiment 2:
Hetastarch 130/0.4 6 grams
4.2 grams, sodium chloride
Water for injection is added to 100 milliliters
Hetastarch is dissolved in water for injection, and 90 DEG C of agitating heating 15 minutes, add sodium chloride stirring and dissolving, and 90 DEG C of agitating heating 10 minutes, filter, fill, sterilizing, to obtain final product.
Embodiment 3:
Hetastarch 130/0.4 7 grams
2 grams, sodium chloride
Water for injection is added to 100 milliliters
Hetastarch is dissolved in water for injection, and 90 DEG C of agitating heating 15 minutes, add sodium chloride stirring and dissolving, and 90 DEG C of agitating heating 10 minutes, filter, fill, sterilizing, to obtain final product.
Embodiment 4:
Hetastarch 130/0.4 4 grams
4.5 grams, sodium chloride
Water for injection is added to 100 milliliters
Hetastarch is dissolved in water for injection, and 90 DEG C of agitating heating 15 minutes, add sodium chloride stirring and dissolving, and 90 DEG C of agitating heating 10 minutes, filter, fill, sterilizing, to obtain final product.
Experimental example:
Adult healthy mongrel, male and female, femoral artery, vein is isolated under local anaesthesia, insert conduit respectively, ductus arteriosus is connected with cardiac function detector to detect its arterial pressure, and make Canis familiaris L. blood-letting be 40-50mmHg to mean arterial pressure (MAP), blood-letting time controling was at about 15 minutes, after making this blood pressure maintain 1 hour, input the embodiment of the present invention 2 pharmaceutical composition, comparative example 1, comparative example 2 pharmaceutical composition by 8ml/kg.
Comparative example 1:7.2% sodium chloride and 6% hetastarch (mean molecule quantity 130,000), preparation method is with the embodiment of the present invention 2.
Comparative example 2:4.2% sodium chloride and 7.6% hetastarch (mean molecule quantity 40,000), preparation method is with the embodiment of the present invention 2.
Blood pressure and urine volume is detected in transfusion latter 4 hours examples.
In following table, blood pressure is the percent returning to basic blood pressure level, urine volume unit be ml/kg body weight/hour.
(continuous upper table)
Visible, the recovery blood pressure that pharmaceutical composition of the present invention can be rapid and lasting, and urine volume will be caused excessively to increase owing to taking in excess moisture.
Claims (6)
1. a pharmaceutical composition, comprises 2-4.5%(w/v) sodium chloride and 3-7%(w/v) hetastarch, and the water for injection of surplus, wherein, the mean molecule quantity of described hetastarch is 130000 ± 20000 dalton.
2. pharmaceutical composition according to claim 1, is characterized in that, said composition comprises 4.2%(w/v) sodium chloride and 6%(w/v) hetastarch.
3. pharmaceutical composition according to claim 1, is characterized in that, described hetastarch degree of exchange is 0.4 ± 0.1.
4. pharmaceutical composition according to claim 1, is characterized in that, described hetastarch degree of exchange is 0.4 ± 0.1, C2: C6 be greater than 8.
5. the preparation method of the pharmaceutical composition in claim 1-4 described in any one, comprising: hetastarch is dissolved in water for injection, 80-95 DEG C of agitating heating 10-20 minute, then add sodium chloride stirring and dissolving, 80-95 DEG C of agitating heating 5-20 minute, filter, fill, sterilizing, to obtain final product.
6. the pharmaceutical composition in claim 1-4 described in any one is for the preparation of the purposes of the medicine for the treatment of hemorrhagic shock.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310585559.0A CN104644669A (en) | 2013-11-19 | 2013-11-19 | Plasma substitute medicine composition used in first aid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310585559.0A CN104644669A (en) | 2013-11-19 | 2013-11-19 | Plasma substitute medicine composition used in first aid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104644669A true CN104644669A (en) | 2015-05-27 |
Family
ID=53236639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310585559.0A Pending CN104644669A (en) | 2013-11-19 | 2013-11-19 | Plasma substitute medicine composition used in first aid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104644669A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1235833A (en) * | 1998-05-15 | 1999-11-24 | 赵超英 | Novel drug composition for treating and curing and its preparing method |
| CN1739561A (en) * | 2005-09-23 | 2006-03-01 | 赵超英 | Application of high permeability medicine composition in preparing pre-nacrosis medicine |
| CN101209344A (en) * | 2006-12-28 | 2008-07-02 | 赵超英 | Application of hyperosmotic fluid composition in preparing medicament for improving wound healing |
| CN101579307A (en) * | 2008-05-14 | 2009-11-18 | 北京申科联华科技有限公司 | Application of hypertonic injection to preparation of medicament accelerating wound healing |
-
2013
- 2013-11-19 CN CN201310585559.0A patent/CN104644669A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1235833A (en) * | 1998-05-15 | 1999-11-24 | 赵超英 | Novel drug composition for treating and curing and its preparing method |
| CN1739561A (en) * | 2005-09-23 | 2006-03-01 | 赵超英 | Application of high permeability medicine composition in preparing pre-nacrosis medicine |
| CN101209344A (en) * | 2006-12-28 | 2008-07-02 | 赵超英 | Application of hyperosmotic fluid composition in preparing medicament for improving wound healing |
| CN101579307A (en) * | 2008-05-14 | 2009-11-18 | 北京申科联华科技有限公司 | Application of hypertonic injection to preparation of medicament accelerating wound healing |
Non-Patent Citations (1)
| Title |
|---|
| 王玉琨 等: "《军事药物学》", 31 May 2013, 第四军医大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Checchia et al. | Nitric oxide delivery during cardiopulmonary bypass reduces postoperative morbidity in children—a randomized trial | |
| Schrier et al. | Effects of hematocrit on renal hemodynamics and sodium excretion in hydropenic and volume-expanded dogs | |
| AU754537B2 (en) | Novel pharmaceutical composition for use in emergency treatment and preparation method thereof | |
| Tiruvoipati et al. | Effectiveness of extracorporeal membrane oxygenation when conventional ventilation fails: valuable option or vague remedy? | |
| TW200423923A (en) | Lactate containing pharmaceutical composition and uses thereof | |
| JP2022500501A (en) | Plasma-containing composition | |
| Jiang et al. | Therapeutic mild hypothermia improves early outcomes in rabbits subjected to traumatic uncontrolled hemorrhagic shock | |
| KR20100017183A (en) | Body-temperature lowering depressant | |
| CN104644668A (en) | First-aid plasma substitute medicine composition and preparation method thereof | |
| Nakao et al. | Modified del Nido cardioplegia and its evaluation in a piglet model | |
| CN104644669A (en) | Plasma substitute medicine composition used in first aid and preparation method thereof | |
| Bauer et al. | Isotonic and hypertonic crystalloid solutions in the critically ill | |
| Gulati et al. | Efficacy of centhaquin as a small volume resuscitative agent in severely hemorrhaged rats | |
| CN102397290B (en) | Hydroxyethyl starch injection and preparation method thereof | |
| Lu et al. | Combined therapy of pentastarch, dexamethasone, and dibutyryl-cAMP or β2-agonist attenuates ischaemia/reperfusion injury of rat lung | |
| Rajmohan et al. | Cardiac arrest during hysteroscopic myomectomy–A combination of venous gas embolism and operative hysteroscopy intravascular absorption syndrome | |
| Kaur et al. | Povidone-iodine toxicity in a child posted for laparoscopic removal of hepatic and renal hydatid cysts | |
| Brettner et al. | The concept of the glycocalyx–Facts that influence perioperative fluid management | |
| CN102755289B (en) | Argatroban injection for resisting thrombus and preparation method thereof | |
| Deng et al. | Initiating Continuous Renal Replacement Therapy in Patients With Transurethral Resection of Prostate Syndrome: A Case Report | |
| RU2431488C1 (en) | Pharmaceutical composition of hydroxyethyl starch in hypertonic saline used as plasma volume replacement solution in low-volume resuscitation | |
| Weiss et al. | Heparin-coated left heart bypass: renal function and hormonal response | |
| Li et al. | Perioperative fluid therapy: A general overview | |
| RU2582219C2 (en) | Artificial plasma extender | |
| Tiwari et al. | Management strategy in mitral valve surgery patient with homozygous sickle cell disease: A case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150527 |